RxDoctor Payments Data

Ramendeep Singh, MD

Family Medicine · Barstow, CANPI 1255777421

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 94 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$328
  • Novo Nordisk$211
  • Pfizer$184
  • AbbVie$114
  • Lilly USA, LLC$111
  • GSK$103
  • plus $486 from 13 others

What the payments were for

  • Food & beverage$1,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,537 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$39,405
Medicare patients
190
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$67,358
JardianceEmpagliflozin42$41,236
EliquisApixaban37$27,361
TrulicityDulaglutide21$22,728
JanuviaSitagliptin Phosphate18$20,580
XareltoRivaroxaban36$19,341
EntrestoSacubitril/Valsartan11$12,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,510
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,350
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,230
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,220
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$2,814
Albuterol Sulfate HfaAlbuterol Sulfate69$2,381
Varenicline Tartrate15$2,322
Atorvastatin Calcium216$2,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$67,35861 claims
Boehringer IngelheimJardiance, Stiolto Respimat$101$47,58753 claims
PfizerEliquis$184$27,36137 claims
Lilly USA, LLCTrulicity$111$22,72821 claims
MerckJanuvia$45$20,58018 claims
Johnson & JohnsonXarelto$15$19,34136 claims
NovartisEntresto$46$12,47411 claims
GSKTrelegy Ellipta$103$9,51015 claims
AbbVieSynthroid$114$1,49739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Barstow

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →